https://www.selleckchem.com/pr....oducts/lomerizine-hc
Planned enrollment is 30 patients over 2.5 years at 27 oncology facilities in Japan. This is the first prospective study to focus on the intracranial response to ICI therapy combined with platinum-based chemotherapy in patients with untreated brain metastases derived from NSCLC. If the study demonstrates intracranial efficacy for this patient population, then this regimen has the potential to become a new treatment option for such individuals. Although the annual incidence of undifferentiated pleomorphic sarcoma (UPS) is extremel
Like
Comment
Share
